JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (22)
2024
-
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441
2023
-
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
Future Oncology, Vol. 19, Núm. 12, pp. 819-828
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Clinical and Translational Oncology
-
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3556-3564
2021
-
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891
2020
-
Latest progress in molecular biology and treatment in genitourinary tumours
Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195
2019
-
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
Critical Reviews in Oncology/Hematology, Vol. 138, pp. 190-206
-
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
European Urology, Vol. 75, Núm. 3, pp. 368-373
-
Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer
Journal of Clinical Oncology, Vol. 37, Núm. 6, pp. 490-503
2017
-
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
The Lancet Respiratory Medicine, Vol. 5, Núm. 5, pp. 435-444
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
-
Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists
Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 508-518
-
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421
-
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190
2016
-
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations
Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
-
Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02
Annals of Oncology, Vol. 27, pp. vi277
2015
-
New advances in genitourinary cancer: evidence gathered in 2014
Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 443-464
2014
-
Erratum to: Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer (Targeted Oncology (2014) 9, (9-24) DOI: 10.1007/s11523-013-0304-7)
Targeted Oncology
-
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma
PLoS ONE, Vol. 9, Núm. 1